4.6 Review

Burden of paediatric influenza in Western Europe: a systematic review

期刊

BMC PUBLIC HEALTH
卷 12, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/1471-2458-12-968

关键词

Influenza; Children; Vaccination; Europe; Burden

资金

  1. MedImmune, LLC, Gaithersburg, Maryland, USA
  2. MedImmune, LLC
  3. MedImmune LLC, Gaithersburg, Maryland, USA, an influenza vaccine manufacturer

向作者/读者索取更多资源

Background: Influenza illness in children causes significant clinical and economic burden. Although some European countries have adopted influenza immunisation policies for healthy children, the debate about paediatric influenza vaccination in most countries of the European Union is ongoing. Our aim was to summarise influenza burden (in terms of health outcomes and economic burden) in children in Western Europe via a systematic literature review. Methods: We conducted a systematic literature search of PubMed, EMBASE, and the Cochrane Library (1970-April 2011) and extracted data on influenza burden in children (defined as aged <= 18 years) from 50 publications (13 reporting laboratory-confirmed influenza; 37 reporting influenza-like illness). Results: Children with laboratory-confirmed influenza experienced hospitalisations (0.3%-20%), medical visits (1.7-2.8 visits per case), antibiotic prescriptions (7%-55%), and antipyretic or other medications for symptomatic relief (76%-99%); young children and those with severe illness had the highest rates of health care use. Influenza in children also led to absenteeism from day care, school, or work for the children, their siblings, and their parents. Average (mean or median) length of absence from school or day care associated with confirmed influenza ranged from 2.8 to 12.0 days for the children, from 1.3 to 6.0 days for their siblings, and from 1.3 to 6.3 days for their parents. Influenza negatively affected health-related quality of life in children with asthma, including symptoms and activities; this negative effect was smaller in vaccinated children than in non-vaccinated children. Conclusions: Influenza burden in children is substantial and has a significant direct impact on the ill children and an indirect impact on their siblings and parents. The identified evidence regarding the burden of influenza may help inform both influenza antiviral use in children and paediatric immunisation policies in European countries.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Allergy

Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study

Andrew N. Menzies-Gow, Claire McBrien, Bindhu Unni, Celeste M. Porsbjerg, Mona Al-Ahmad, Christopher S. Ambrose, Karin Dahl Assing, Anna von Bulow, John Busby, Borja G. Cosio, J. Mark FitzGerald, Esther Garcia Gil, Susanne Hansen, Liam G. aHeaney, Mark Hew, David J. Jackson, Maria Kallieri, Stelios Loukides, Njira L. Lugogo, Andriana Papaioannou, Desiree Larenas-Linnemann, Wendy C. Moore, Luis A. Perez-de-Llano, Linda M. Rasmussen, Johannes M. Schmid, Salman Siddiqui, Marianna Alacqua, Trung N. Tran, Charlotte Suppli Ulrik, John W. Upham, Elleen Wang, Lakmini Bulathsinhala, Victoria A. Carter, Isha Chaudhry, Neva Eleangovan, Ruth B. Murray, Chris A. Price, David B. Price

Summary: This study described real-life patterns of biologic use for severe asthma in multiple countries, showing that most patients continued their initial biologic treatment, while some stopped or switched to a different biologic. Patients who stopped or switched were more likely to have higher baseline blood eosinophil count, higher exacerbation rate, lower lung function, and greater healthcare resource utilization.

JOURNAL OF ASTHMA AND ALLERGY (2022)

Review Infectious Diseases

Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape

Natalie Mazur, Jonne Terstappen, Ranju Baral, Azucena Bardaji, Philippe Beutels, Ursula J. Buchholz, Cheryl Cohen, James E. Crowe, Clare L. Cutland, Linda Eckert, Daniel Feikin, Tiffany Fitzpatrick, Youyi Fong, Barney S. Graham, Terho Heikkinen, Deborah Higgins, Siddhivinayak Hirve, Keith P. Klugman, Leyla Kragten-Tabatabaie, Philippe Lemey, Romina Libster, Yvette Lowensteyn, Asuncion Mejias, Flor M. Munoz, Patrick K. Munywoki, Lawrence Mwananyanda, Harish Nair, Marta C. Nunes, Octavio Ramilo, Peter Richmond, Tracy J. Ruckwardt, Charles Sande, Padmini Srikantiah, Naveen Thacker, Kody A. Waldstein, Dan Weinberger, Joanne Wildenbeest, Dexter Wiseman, Heather J. Zar, Maria Zambon, Louis Bont

Summary: Respiratory syncytial virus (RSV) is a major cause of infant mortality and morbidity in older adults. Efforts are being made to develop RSV vaccines and immunoprophylaxis using various approaches, with 33 candidates currently in clinical development. Understanding antibody targets has led to more rational and structure-based vaccine design. An extended half-life monoclonal antibody for infants is expected to receive regulatory approval within a year. Other approaches include live-attenuated vaccines for older infants, subunit vaccines for pregnant women, and vector and nucleic acid vaccines for older adults. Ensuring access and affordability of RSV vaccines globally is a priority.

LANCET INFECTIOUS DISEASES (2023)

Article Allergy

Impact of the COVID-19 Pandemic on Incidence of Asthma Exacerbations and Hospitalizations in US Subspecialist-Treated Patients with Severe Asthma: Results from the CHRONICLE Study

Wendy C. Moore, Dennis K. Ledford, Donna D. Carstens, Christopher S. Ambrose

Summary: Following COVID-19-related stay-at-home orders and social distancing recommendations, there was a significant reduction in exacerbations, exacerbation-related emergency department visits, and asthma hospitalizations among subspecialist-treated patients with severe asthma. This reduction is likely due to multiple factors, including reduced viral infections resulting from decreased social contact and changes in patient behavior.

JOURNAL OF ASTHMA AND ALLERGY (2022)

Article Immunology

Trends and Changes in Influenza-associated Hospitalizations in Children During 25 Years in Finland, 1993-2018

Janna-Maija Mattila, Tytti Vuorinen, Terho Heikkinen

Summary: The demographics and management of children hospitalized with influenza at Turku University Hospital in Finland changed over a 25-year period. The proportion of children aged <2 years decreased while children aged 6-15 years increased. Hospitalization rates decreased for children aged 1 year and increased for children aged 6-15 years. The duration of hospitalization also shortened.

PEDIATRIC INFECTIOUS DISEASE JOURNAL (2023)

Article Immunology

Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries

Abraham M. Getaneh, Xiao Li, Zhuxin Mao, Caroline K. Johannesen, Elisa Barbieri, Jojanneke van Summeren, Xin Wang, Sabine Tong, Eugenio Baraldi, Emily Phijffer, Caterina Rizzo, Maarten van Wijhe, Terho Heikkinen, Louis Bont, Lander Willem, Mark Jit, Philippe Beutels, Joke Bilcke

Summary: This study evaluates the cost-effectiveness of potential mAb and MI interventions against RSV in infants in six European countries. The results show that the choice between MI or mAb depends on factors such as protection level, price, and feasibility for different countries and scenarios.

VACCINE (2023)

Article Critical Care Medicine

The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study

Joanne G. Wildenbeest, Marie-Noelle Biard, Roy Zuurbier, Koos Korsten, Annefleur C. Langedijk, Peter M. van de Ven, Matthew Snape, Simon B. Drysdale, Andrew J. Pollard, Hannah Robinson, Terho Heikkinen, Steve Cunningham, Thomas O'Neill, Bishoy Rizkalla, Ana Dacosta-Urbieta, Federico Martinon-Torres, Marlies A. van Houten, Louis J. Bont

Summary: Respiratory syncytial virus (RSV) is a major cause of hospitalisation in infants. The burden of RSV infection in healthy term infants has been determined in a multicentre, prospective, observational study. The study found that RSV-associated acute respiratory infection causes substantial morbidity, leading to hospitalisation of one in every 56 healthy term-born infants in high-income settings. Immunisation of pregnant women or healthy term-born infants during their first winter season could have a major effect on the health-care burden caused by RSV infections. Rating: 9/10

LANCET RESPIRATORY MEDICINE (2023)

Review Medicine, Research & Experimental

Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review

Stephanie Korn, Bill Cook, Lisa J. Simpson, Jean-Pierre Llanos, Christopher S. Ambrose

Summary: RCTs have shown differential results of biologics in severe, uncontrolled asthma patients based on baseline blood eosinophil count (BEC). We summarized the effects of biologics on annualized asthma exacerbation rate (AAER) in placebo-controlled RCTs by baseline BEC, as well as other outcomes. The efficacy of biologics in reducing AAER in severe asthma patients increases with higher baseline BEC, with variations among different biologics due to differing mechanisms of action.

ADVANCES IN THERAPY (2023)

Article Critical Care Medicine

Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials

Jonathan Corren, Andrew Menzies-Gow, Geoffrey Chupp, Elliot Israel, Stephanie Korn, Bill Cook, Christopher S. Ambrose, Asa Hellqvist, Stephanie L. Roseti, Nestor A. Molfino, Jean-Pierre Llanos, Neil Martin, Karin Bowen, Janet M. Griffiths, Jane R. Parnes, Gene Colice

Summary: In two clinical trials, it was found that Tezepelumab significantly reduced the risk of exacerbations and improved other outcomes in patients with severe, uncontrolled asthma, regardless of baseline blood eosinophil counts, fractional exhaled nitric oxide levels, or allergy status.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

Letter Critical Care Medicine

Reply to Lipworth and Chan

Christopher S. Ambrose, Elliot Israel, Karin Bowen, Jean-Pierre Llanos, Neil Martin, Bill Cook, Asa Hellqvist, Stephanie Korn, Andrew Menzies-Gow, Stephanie L. Roseti, Nestor A. Molfino, Janet M. Griffiths, Jane R. Parnes

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

Article Allergy

Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma

Bradley E. Chipps, Weily Soong, Reynold A. Panettieri Jr, Warner Carr, Hitesh Gandhi, Wenjiong Zhou, Bill Cook, Jean-Pierre Llanos, Christopher S. Ambrose

Summary: The number of asthma triggers is positively associated with disease burden in patients with severe asthma in the United States, affecting disease control, quality of life, and work productivity.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2023)

Article Immunology

Burden of Respiratory Syncytial Virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years

Marco Del Riccio, Peter Spreeuwenberg, Richard Osei-Yeboah, Caroline K. Johannesen, Liliana Vazquez Fernandez, Anne C. Teirlinck, Xin Wang, Terho Heikkinen, Mathieu Bangert, Saverio Caini, Harry Campbell, John Paget

Summary: This study estimated that an average of 245,244 children aged under 5 years are hospitalized annually due to RSV in the EU, with the highest hospitalization rates in children aged less than 2 months (71.6 per 1000 children).

JOURNAL OF INFECTIOUS DISEASES (2023)

Article Infectious Diseases

Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data

Deidre Wilkins, Annefleur C. Langedijk, Robert Jan Lebbink, Christopher Morehouse, Michael E. Abram, Bahar Ahani, Anastasia A. Aksyuk, Eugenio Baraldi, Tyler Brady, Albert Tian Chen, Hsin Chi, Eun Hwa Choi, Robert Cohen, Daria M. Danilenko, Vancheswaran Gopalakrishnan, Anne Greenough, Terho Heikkinen, Mitsuaki Hosoya, Christian Keller, Elizabeth J. Kelly, Leyla Kragten-Tabatabaie, Federico Martinon-Torres, Abiel Homero Mascarenas de los Santos, Marta C. Nunes, Maria Angelica Palomino, Jesse Papenburg, Jeffrey M. Pernica, Peter Richmond, Renato Stein, Kevin M. Tuffy, Charl Verwey, Mark T. Esser, David E. Tabor, Louis J. Bont, INFORM RSV Study Grp

Summary: This study evaluated the geotemporal distribution of RSV A and RSV B between 2015 and 2021 and functionally characterized the nirsevimab binding-site substitutions during this period. The results showed that the nirsevimab binding site remained highly conserved, with only a few rare mutations affecting nirsevimab neutralization emerging between 2016 and 2021. The genetic diversity of RSV fusion protein was lower compared to influenza hemagglutinin and SARS-CoV-2 spike proteins.

LANCET INFECTIOUS DISEASES (2023)

Article Immunology

Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: A multi-country prospective cohort study in Europe

Zhuxin Mao, Xiao Li, Ana Dacosta-Urbieta, Marie-Noelle Billard, Joanne Wildenbeest, Koos Korsten, Federico Martinon-Torres, Terho Heikkinen, Steve Cunningham, Matthew D. Snape, Hannah Robinson, Andrew J. Pollard, Maarten Postma, Benoit Dervaux, Niel Hens, Louis Bont, Joke Bilcke, Philippe Beutels

Summary: The study aimed to evaluate the costs and health-related quality of life (HRQoL) effects associated with respiratory syncytial virus (RSV) infection in infants and their caregivers. The results showed that RSV infection resulted in significant cost burden and loss of HRQoL.

VACCINE (2023)

Review Medicine, Research & Experimental

Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review

Jonathan A. Bernstein, Jean-Pierre Llanos, Gillian Hunter, Neil Martin, Christopher S. Ambrose

Summary: This study describes the reduction of annualized asthma exacerbation rate (AAER) from randomized controlled trials (RCTs) in patients with allergic severe asthma. The study found that the efficacy of biologics varied considerably overall and by baseline blood eosinophil count (BEC), with tezepelumab consistently demonstrating the greatest reduction in AAER across all subgroups.

ADVANCES IN THERAPY (2023)

Review Allergy

Effect of Biologic Therapies on Airway Hyperresponsiveness and Allergic Response: A Systematic Literature Review

Joseph Spahn, Christopher E. Brightling, Paul M. O'Byrne, Lisa J. Simpson, Nestor A. Molfino, Christopher S. Ambrose, Neil Martin, Teal S. Hallstrand

Summary: This study was funded by AstraZeneca and Amgen Inc.

JOURNAL OF ASTHMA AND ALLERGY (2023)

暂无数据